$2.20
+0.24 (+12.24%)
Open$2.03
Previous Close$1.96
Day High$2.24
Day Low$2.03
52W High$29.32
52W Low$16.08
Volume—
Avg Volume193.5K
Market Cap5.10M
P/E Ratio37.54
EPS$0.69
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,157.3% upside
Current
$2.20
$2.20
Target
$27.66
$27.66
$20.34
$27.66 avg
$35.38
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.53M | 1.54M | 1.49M |
| Net Income | 146.8K | 155.5K | 142.3K |
| Profit Margin | 9.6% | 10.1% | 9.6% |
| EBITDA | 279.3K | 246.3K | 227.4K |
| Free Cash Flow | 124.0K | 159.2K | 163.1K |
| Rev Growth | +19.5% | +5.1% | +5.0% |
| Debt/Equity | 0.44 | 0.57 | 0.57 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |